IRCT20200105046010N81招募中Unknown
Bioequivalence study of Dasatinib 100mg tablet manufactured by Actero pharma (Dotixa) versus Sprycel 100 mg in healthy volunteers in the fasted condition
Actero Pharma Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to dasatinib
研究者
相似试验
招募中
不适用
Bioequivalence study of Dasatinib 50 mg tabletIRCT20200623047902N22Zistdaru danesh Co.48
招募中
不适用
In-vivo Bioequivalence Test of Dasatinib tablets with brand drug (SPRYCEL® 140 mg, Rosche, Switzerlandd)Plasma drug concentration.IRCT20200105046010N56anoalvand Pharmaceutical Co24
招募中
不适用
In-vivo Bioequivalence Test of Dasatonib tablet 100 mg Abidi Pharma with brand drug (SPRYCEL® 100 mg FC Tab, Bristol-Myers Squibb, UK)Bio equivalence test.IRCT20200105046010N66Abidi Pharmaceutical Company24
尚未招募
4 期
Bioequivalence Studies of Dasatinib 100 MgMyeloma MultipleNCT05944783Centro de Atencion e Investigacion Medica46
尚未招募
不适用
Study to compare efficacy & safety of Dasatinib with respect to Imatinib in newly diagnosed cases of chronic phase of chronic myeloid leukemia in terms of early response assessment at three months of therapyCTRI/2022/03/041208aiims rishikesh